Annals of Hematology最新文献_第3页

Internal tandem duplications of FLT3 containing exogenous sequences are associated with poor clinical outcomes in acute myeloid leukemia. 含有外源性序列的FLT3的内部串联重复与急性髓系白血病的不良临床结果相关。

IF 2.4 3区医学

Annals of Hematology Pub Date : 2025-09-26 DOI: 10.1007/s00277-025-06618-1

Shao-Tong Li, Xiu-Min Shi, Qiu-Ju Liu, Ye-Hui Tan, Hai Lin, Yan-Ping Yang, Jing-Nan Sun, Yun-Wei Zhang, Long Su, Su-Jun Gao

{"title":"Internal tandem duplications of FLT3 containing exogenous sequences are associated with poor clinical outcomes in acute myeloid leukemia.","authors":"Shao-Tong Li, Xiu-Min Shi, Qiu-Ju Liu, Ye-Hui Tan, Hai Lin, Yan-Ping Yang, Jing-Nan Sun, Yun-Wei Zhang, Long Su, Su-Jun Gao","doi":"10.1007/s00277-025-06618-1","DOIUrl":"https://doi.org/10.1007/s00277-025-06618-1","url":null,"abstract":"The heterogeneity in internal tandem duplications (ITDs) of FMS-like tyrosine kinase 3 (FLT3) results in diverse clinical outcomes for acute myeloid leukemia (AML) patients with FLT3-ITD mutations. This study retrospectively analyzed 124 FLT3-ITD-positive AML patients, aiming to evaluate How ITDs with exogenous sequences affect the response to induction therapy and long-term prognosis. Among them, 45.97% (57/124) had ITDs with exogenous sequences, classified as the insertion group. The remaining 54.03% (67/124) had only repetitions of the original FLT3 sequence, classified as the duplication group. Comparisons between these two groups revealed that the rates of composite complete remission (CRc) (59.09% vs. 81.03%, P = 0.017) and negative measurable residual disease (MRD) identified by multiparameter flow cytometry (MFC) (25.00% vs. 48.28%, P = 0.018) were significantly lower in the insertion group than those in the duplication group after the first cycle of induction therapy. Moreover, survival analysis conducted on 68 patients who received at least two cycles of consolidation therapy revealed that patients in the insertion group had significantly lower relapse-free survival (RFS) (2-year RFS: 50.70% ± 10.40% vs. 71.40% ± 8.90%, P = 0.033) and overall survival (OS) (2-year OS: 52.90% ± 10.20% vs. 79.00% ± 7.90%, P = 0.017) compared with those in the duplication group. Cox regression analysis identified ITD types, DNMT3A co-mutations, MFC-MRD after the second cycle (C2) of chemotherapy and allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the first CR (CR1) as independent factors affecting RFS and OS. Furthermore, nomograms were employed to predict RFS and OS, and a new prognostic re-stratification model based on ITD types for FLT3-ITD-positive AML was proposed.","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145147806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy of radiotherapy in primary mediastinal diffuse large B-cell lymphoma: a systematic review and meta-analysis of 1,392 patients. 放疗治疗原发性纵隔弥漫性大b细胞淋巴瘤的疗效：1392例患者的系统回顾和荟萃分析。

IF 2.4 3区医学

Annals of Hematology Pub Date : 2025-09-25 DOI: 10.1007/s00277-025-06530-8

Dongyu Zhuang, Silan Huang, Peng Zhang, Dexin Lei, Yanlou Wang, Honglian Liu, Man Nie, Yi Xia

{"title":"Efficacy of radiotherapy in primary mediastinal diffuse large B-cell lymphoma: a systematic review and meta-analysis of 1,392 patients.","authors":"Dongyu Zhuang, Silan Huang, Peng Zhang, Dexin Lei, Yanlou Wang, Honglian Liu, Man Nie, Yi Xia","doi":"10.1007/s00277-025-06530-8","DOIUrl":"https://doi.org/10.1007/s00277-025-06530-8","url":null,"abstract":"Primary mediastinal B-cell lymphoma (PMBCL) patients who achieve a complete response (CR) following first-line immunochemotherapy tend to have favorable outcomes, even without subsequent radiotherapy (RT). However, it remains unclear whether the survival of patients who do not achieve CR after first-line therapy and subsequently receive radiotherapy is comparable to that of CR patients who undergo observation alone. To address this gap, we conducted a systematic review and meta-analysis to compare progression-free survival (PFS) and overall survival (OS) between CR patients who forgo radiotherapy and non-CR patients who receive consolidative radiotherapy. Additionally, we examined potential influencing factors to provide evidence-based guidance for clinical treatment strategies. A comprehensive search of multiple databases (PubMed, EMBASE, and Cochrane Library) was conducted for the period from January 1, 2012, to September 1, 2024. Using predefined keywords and screening procedures, 15 studies were ultimately included. The primary endpoint was PFS, with OS as a secondary endpoint. Subgroup analyses were performed based on chemotherapy regimens. This systematic review and meta-analysis of 15 studies demonstrated that consolidative radiotherapy significantly improves PFS in patients with partial remission (PR) after first-line immunochemotherapy, with an overall risk ratio (RR) of 1.11 (95% confidence interval [CI]: 1.05-1.16). For OS, the RR was 1.04 (95% CI: 0.97-1.12), crossing the line of no effect, which suggests that consolidative radiotherapy does not have a statistically significant impact on OS. Consolidative radiotherapy improves PFS in patients with PMBCL, but its effect on OS is not statistically significant.","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145136090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical and molecular features of primary spinal epidural lymphomas. 原发性脊髓硬膜外淋巴瘤的临床及分子特征。

IF 2.4 3区医学

Annals of Hematology Pub Date : 2025-09-25 DOI: 10.1007/s00277-025-06554-0

Louisa Adolph, Veit M Stoecklein, Verena Passerini, Michael Heide, Philipp Karschnia, Stefan Zausinger, Louisa von Baumgarten, Michael von Bergwelt-Baildon, Jörg Christian Tonn, Sophia Stoecklein, Niklas Thon, Christian Schichor, Martina Rudelius, Oliver Weigert

{"title":"Clinical and molecular features of primary spinal epidural lymphomas.","authors":"Louisa Adolph, Veit M Stoecklein, Verena Passerini, Michael Heide, Philipp Karschnia, Stefan Zausinger, Louisa von Baumgarten, Michael von Bergwelt-Baildon, Jörg Christian Tonn, Sophia Stoecklein, Niklas Thon, Christian Schichor, Martina Rudelius, Oliver Weigert","doi":"10.1007/s00277-025-06554-0","DOIUrl":"https://doi.org/10.1007/s00277-025-06554-0","url":null,"abstract":"Lymphomas confined to the spinal epidural space at initial diagnosis are rare and referred to as primary spinal epidural lymphoma (PSEL). This study presents clinical, histopathological, and molecular insights from 13 PSEL cases, including follicular lymphoma (PSEL-FL, N = 4), extranodal marginal zone lymphoma (PSEL-MZL, N = 3), diffuse large B-cell lymphoma (PSEL-DLBCL, N = 5), and Burkitt lymphoma (PSEL-BL, N = 1). Despite localized presentation at initial diagnosis, PSEL with aggressive histologies demonstrated remarkably unfavorable outcomes, contrasting the highly indolent clinical course observed in indolent PSEL, particularly PSEL-FL. Molecular analysis showed similarities to nodal counterparts and separation by entity. Comparison of PSEL-FL and classic FL revealed activated tumor microenvironment-associated pathways, potentially supporting extranodal lymphoma growth in this rarely affected spinal epidural site.","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145135940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comprehensive analysis of the clinical feature, myeloid neoplasm-related gene mutation profiles and T cell diversity acquired pure red cell aplasia. 综合分析临床特点、髓系肿瘤相关基因突变谱和T细胞多样性获得纯红细胞发育不全。

IF 2.4 3区医学

Annals of Hematology Pub Date : 2025-09-25 DOI: 10.1007/s00277-025-06638-x

Yuemin Gong, Xingxing Chai, Xiaoqing Liu, Yawen Zhang, Yue Li, Yunlong Li, Jianping Hao, Guangsheng He

{"title":"Comprehensive analysis of the clinical feature, myeloid neoplasm-related gene mutation profiles and T cell diversity acquired pure red cell aplasia.","authors":"Yuemin Gong, Xingxing Chai, Xiaoqing Liu, Yawen Zhang, Yue Li, Yunlong Li, Jianping Hao, Guangsheng He","doi":"10.1007/s00277-025-06638-x","DOIUrl":"https://doi.org/10.1007/s00277-025-06638-x","url":null,"abstract":"Purpose: Acquired pure red cell aplasia (PRCA) is a kind of rare bone marrow failure disease characterized by destruction of erythrocyte by the immune system. However, the diverse etiologies of acquired PRCA make its pathogenesis largely unclear.Materials and methods: We portrayed the clinicopathologic, mutation and TCR rearrangement profiles of 64 primary PRCA cases and 104 large granular lymphocytic leukemia (LGLL)-associated PRCA, and tried to reveal the association factors of CsA response.Results: We found that gene mutations were detected in 39.7% of acquired PRCA who were older than 40 years, with DNMT3A, KMT2A and TP53 being the top 3 mutation genes. KMT2A mutation was only detected in patients with normal reticulocyte (Ret)%, while IDH1 mutation only occurred in patients with normal CD3 + CD8+/Lym%. For LGLL-associated PRCA patients, TRBV6_TRBJ2 was the most frequent dominant clonotype and the proportion of each dominant clone decreased following the remission of anemia. The response rate of LGLL-associated PRCA to CsA treatment was lower than primary PRCA (56.4% vs. 77.4%). β2-MG dysregulation, MF dysregulation were unfavorable factors for the response to CsA in PRCA patients, while other clinical information, mutated genes, number of mutated genes, mean VAF, number of TCR clones in PRCA patients did not significantly affect the response to CsA.Conclusion: This study described the clinical features, mutation landscape and TCR rearrangement profile in a relatively larger PRCA cohort, which may contribute to the clear perception of PRCA and the development of more potent treatment approaches.","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145135959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Framework for the comprehensive screening for endocrine disorders in patients with transfusion-dependent thalassemia in low-resource settings. 低资源环境中输血依赖型地中海贫血患者内分泌紊乱综合筛查框架。

IF 2.4 3区医学

Annals of Hematology Pub Date : 2025-09-24 DOI: 10.1007/s00277-025-06577-7

Saadia Abbas, Muhammad Osama Khan, Aahan Arif, Hafsa Majid, Lena Jafri, Aisha Shaikh, Khadija Humayun, Aysha Habib Khan, Bushra Moiz

{"title":"Framework for the comprehensive screening for endocrine disorders in patients with transfusion-dependent thalassemia in low-resource settings.","authors":"Saadia Abbas, Muhammad Osama Khan, Aahan Arif, Hafsa Majid, Lena Jafri, Aisha Shaikh, Khadija Humayun, Aysha Habib Khan, Bushra Moiz","doi":"10.1007/s00277-025-06577-7","DOIUrl":"https://doi.org/10.1007/s00277-025-06577-7","url":null,"abstract":"Despite advances in managing transfusion-dependent thalassemia (TDT), endocrine complications continue to be a major concern, especially in low-resource settings where delayed diagnosis and inadequate screening lead to higher morbidity. This study aims to develop a practical, evidence-based framework for screening endocrine and metabolic disorders in TDT patients aged 1-16 years in resource-limited environments. Five major guidelines were reviewed, including those from the Thalassemia International Federation (2025), UK Thalassemia Standards (2023), Italian Society for Thalassemia (2022), International Network on Endocrine Complications in Thalassemia (2013), and Oakland Children's Hospital (2012). A multidisciplinary panel of experts analyzed these guidelines along with local data to create a structured screening approach. Local literature highlights significant endocrine challenges, including stunted growth (50.5%, 95% CI: 29.6-71.4) and hypogonadism or delayed puberty (45.8%, 95% CI: -6.5-98.2). Less common issues include hypothyroidism (19.9%), hypoparathyroidism (12.8%), and impaired glucose metabolism (5.0%). A comparative analysis reveals that all guidelines emphasize the importance of clinical evaluation and laboratory testing. However, there are variations in testing panels and screening protocols. The proposed framework highlights clinical assessment as the first step, followed by targeted laboratory testing when resources are limited. Key recommendations include optimizing transfusion and iron chelation to reduce complications, as well as age-specific screening for early detection of endocrinopathies in patients with TDT. This consensus-based approach seeks to standardize endocrine screening for TDT patients, promoting early intervention and referral. Successful implementation will involve training healthcare providers to improve thalassemia care in low-resource settings.","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145129891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Establishing prognostic markers associated with neutrophil extracellular traps and the activated contact system in thrombotic microangiopathy. 在血栓性微血管病中建立与中性粒细胞胞外陷阱和活化接触系统相关的预后标志物。

IF 2.4 3区医学

Annals of Hematology Pub Date : 2025-09-24 DOI: 10.1007/s00277-025-06612-7

Su Sung Kim, Ja Yoon Gu, Sung Yoon Choi, Yujin Jung, Yoon Hwan Chang, Seon Young Kim, Hyun Kyung Kim

{"title":"Establishing prognostic markers associated with neutrophil extracellular traps and the activated contact system in thrombotic microangiopathy.","authors":"Su Sung Kim, Ja Yoon Gu, Sung Yoon Choi, Yujin Jung, Yoon Hwan Chang, Seon Young Kim, Hyun Kyung Kim","doi":"10.1007/s00277-025-06612-7","DOIUrl":"https://doi.org/10.1007/s00277-025-06612-7","url":null,"abstract":"Thrombotic microangiopathy (TMA) is a life-threatening thrombotic disorder. Neutrophil extracellular traps (NETs) and activation of the contact system are known to promote and propagate the formation of thrombus. Our study assessed the prognostic values of multiple NET markers and a contact system activation marker in patients with clinically suspected TMA. Patients (n = 138) with clinically suspected TMA were analyzed for the circulating levels of NET markers (neutrophil elastase, histone-DNA complexes, citrullinated histone H3 [Cit H3], and cell-free double-stranded DNA [dsDNA]); the contact system activation marker (activated factor XII [factor XIIa]); and other TMA-associated markers (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 [ADAMTS13] activity, von Willebrand factor antigen [vWF:Ag], von Willebrand factor ristocetin cofactor activity [vWF:Rco], and platelet counts). Low ADAMTS13 activity (hazard ratio [HR]: 4.85, P = 0.033), high vWF:Rco (HR: 9.46, P = 0.037), low platelet counts (HR: 7.45, P = 0.017), and high histone-DNA complexes (HR: 8.43, P = 0.015) were identified as independent markers of high mortality in multivariable Cox proportional hazards regression analysis. ADAMTS13, vWF:Rco, platelet counts, and histone-DNA complexes can be useful markers for identifying TMA patients at high risk of mortality.","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145129944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

USP7 mutations are associated with adverse outcomes in pediatric T cell acute lymphoblastic leukemia and lymphoma. USP7突变与儿童T细胞急性淋巴细胞白血病和淋巴瘤的不良结局相关。

IF 2.4 3区医学

Annals of Hematology Pub Date : 2025-09-22 DOI: 10.1007/s00277-025-06582-w

Jun Li, Yuan Yuan, Feng-Feng Niu, Ying Wang, Wei Lin, Rui-Dong Zhang, Ling Jin, Yan-Long Duan, Chao Gao

{"title":"USP7 mutations are associated with adverse outcomes in pediatric T cell acute lymphoblastic leukemia and lymphoma.","authors":"Jun Li, Yuan Yuan, Feng-Feng Niu, Ying Wang, Wei Lin, Rui-Dong Zhang, Ling Jin, Yan-Long Duan, Chao Gao","doi":"10.1007/s00277-025-06582-w","DOIUrl":"https://doi.org/10.1007/s00277-025-06582-w","url":null,"abstract":"USP7 alterations in pediatric T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) remains incompletely understood. We investigated the clinical features and long-term outcomes associated with USP7 mutations in a cohort of 313 pediatric T-ALL/LBL patients. USP7 and NOTCH1 mutations were detected by Sanger sequencing and their association with prognosis were analyzed. Cox regression and nomogram models were used to evaluate prognostic importance. We identified 12 patients with USP7 heterozygous mutations (10 T-ALL, 2 T-LBL) with older age and higher proportion of not remission at day 15 morphological evaluation. Patients with USP7 mutation showed significantly worse event-free survival (EFS) and overall survival (OS) compared to wild-type cases, both in T-ALL and combined T-ALL/LBL cohorts. Concurrent analysis of USP7 and NOTCH1 mutations revealed USP7mutNOTCH1wt genotype was associated with the worst, whereas USP7wtNOTCH1mut was linked to the best EFS and OS in both T-ALL and T-ALL/LBL groups. USP7 mutation, pre-consolidation MRD ≥ 10-4 and CNS leukemia were independent adverse factors for EFS, and the former two were also predictors for OS. USP7 mutation status was validated as the most influential prognostic factor, with prediction models including USP7 status showing enhanced accuracy. In conclusion, USP7 mutations define a subset of T-ALL/LBL patients with adverse outcomes on conventional intensive treatment.","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145111929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Imatinib and blinatumomab successfully rescued a pediatric B-ALL patient with TERF2::PDGFRB fusion resistant to dasatinib and chemotherapy. 伊马替尼和布利纳单抗成功拯救了一名对达沙替尼和化疗耐药的TERF2::PDGFRB融合的儿童B-ALL患者。

IF 2.4 3区医学

Annals of Hematology Pub Date : 2025-09-20 DOI: 10.1007/s00277-025-06620-7

Fanghua Ye, Leyuan Wang, Yujie Qian, Wenjun Deng, Yan Yu, Liangchun Yang

引用次数: 0

Treatment persistence and overall survival in myelofibrosis treated with ruxolitinib were not affected by the covid-19 pandemic, despite the reduced starting dose: Analysis of AIFA registries. 使用ruxolitinib治疗的骨髓纤维化患者的治疗持久性和总生存率不受covid-19大流行的影响，尽管起始剂量降低：AIFA登记分析。

IF 2.4 3区医学

Annals of Hematology Pub Date : 2025-09-20 DOI: 10.1007/s00277-025-06601-w

Massimo Breccia, Simone Celant, Francesca Palandri, Francesco Passamonti, Pier Paolo Olimpieri, Valentina Summa, Annalisa Guarcello, Giuseppe Alberto Palumbo, Fabrizio Pane, Paola Guglielmelli, Pierluigi Zinzani, Paolo Corradini, Pierluigi Russo

{"title":"Treatment persistence and overall survival in myelofibrosis treated with ruxolitinib were not affected by the covid-19 pandemic, despite the reduced starting dose: Analysis of AIFA registries.","authors":"Massimo Breccia, Simone Celant, Francesca Palandri, Francesco Passamonti, Pier Paolo Olimpieri, Valentina Summa, Annalisa Guarcello, Giuseppe Alberto Palumbo, Fabrizio Pane, Paola Guglielmelli, Pierluigi Zinzani, Paolo Corradini, Pierluigi Russo","doi":"10.1007/s00277-025-06601-w","DOIUrl":"https://doi.org/10.1007/s00277-025-06601-w","url":null,"abstract":"We analyzed the outcome of 2229 patients with myelofibrosis (MF) treated with ruxolitinib before and after the COVID-19 pandemic. Two populations of MF were defined from the AIFA web monitoring registries: the pre-COVID-19 (1703, 76.4%) and the post-COVID-19 (526, 23.6%) cohorts. The two populations were balanced using the Inversity Probability of Treatment Weighting. The median age was 69 years and 73 years in the pre- and post- COVID-19 era, respectively. There were no differences in spleen diameters at baseline prior to ruxolitinib in the two groups, but a difference in median spleen volume was noted (961 cm3 in the pre-era and 788.3 cm3 in the post-era). Overall, intermediate-2 IPSS risk were 67.2% in the pre- and 72% in the post-era, whereas the high-risk category was 32.7% and 27.9%, respectively. More patients started on a reduced dose in the post-COVID-19 era (73.5% versus 65% in the pre-era). After adjusting for the differences, an analysis of overall survival revealed no differences between the two groups (HR 0.875, p > 0.05). Patients who started ruxolitinib after COVID-19 had similar probability to stop treatment in the follow-up (HR 0.956, p > 0.05). The results indicate that COVID-19 did not affect the duration of treatment and the relative OS.","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145090988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical features and prognosis analysis of patients with follicular lymphoma: a real-world study in China. 中国滤泡性淋巴瘤患者的临床特征及预后分析。

IF 2.4 3区医学

Annals of Hematology Pub Date : 2025-09-20 DOI: 10.1007/s00277-025-06617-2

Yang Su, Qi Hu, Weili Zhao, Chi Liu, Li Wang, Shu Cheng, Pengpeng Xu, Linlin Liu, Wenzhong Yang

{"title":"Clinical features and prognosis analysis of patients with follicular lymphoma: a real-world study in China.","authors":"Yang Su, Qi Hu, Weili Zhao, Chi Liu, Li Wang, Shu Cheng, Pengpeng Xu, Linlin Liu, Wenzhong Yang","doi":"10.1007/s00277-025-06617-2","DOIUrl":"https://doi.org/10.1007/s00277-025-06617-2","url":null,"abstract":"Follicular lymphoma (FL) is a common indolent B-cell lymphoma with heterogeneous clinical behavior. Prognostic data from Chinese real-world populations remain Limited. We retrospectively analyzed 118 patients with newly diagnosed FL treated at our center from January 2022 to December 2024. Clinical features, laboratory indicators, immune markers, and treatment responses were evaluated. Survival outcomes were analyzed using Kaplan-Meier and Cox regression methods. The follow-up ended on January 31, 2025, with a median follow-up duration of 11.2 months (range, 1.1-36.0 months). The 2-year overall survival (OS) and progression-free survival (PFS) rates were 90.1% and 69.7%, respectively. The overall complete response (CR) rate was 60.2%. In univariate analysis, several factors including pathological grade 3B/composite histology, B symptoms, low NK cell percentage (< 8%), low CD4+ T cell levels (< 30%), CD5 positivity, CD10 negativity, and MUM1 positivity were significantly associated with poor OS and/or PFS. Multivariate Cox regression revealed that pathological grade 3B/composite histology was an independent risk factor for PFS (HR 2.933, P = 0.035), while NK cell percentage < 8% independently predicted worse OS (HR 0.067, P = 0.005). This study validates the prognostic significance of pathological grade and NK cell levels in a Chinese real-world FL population. Peripheral blood NK cell percentage may serve as a clinically useful biomarker for host immune status and prognosis. The findings support further investigation into immune-based prognostic markers and therapeutic strategies in FL.","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145090939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0